Sutro Biopharma, Inc.

95 articles with Sutro Biopharma, Inc.

• Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC

  9/21/2020

  Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held during the World ADC Digital Event.

• Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting

  9/9/2020

  Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced further STRO-002 updated interim Phase 1 safety and preliminary efficacy data in ovarian cancer,

• Sutro Biopharma to Present at Two Upcoming Investor Conferences - Sep 03, 2020

  9/3/2020

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the following investor conferences in September

• Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting

  9/2/2020

  Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression

• Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

  8/25/2020

  Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.

• Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing

  8/11/2020

  Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations

• Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/10/2020

  Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Bill Newell, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 11:30 a.m. EDT / 8:30 a.m. PDT.

• Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments

  8/6/2020

  Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Meeting II in June Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors STRO-001 Dose Escalation Ongoing in Phase 1 Clinical Trial for Multiple Myeloma and Lymphoma Sutro's Partner Merck KGaA, Unveiled Preclinical Data from the Collaboration's potential First-in-Class Bispecific Antibody-Drug

• Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

  6/22/2020

  Additionally, Sutro's partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration's pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1

• Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020

  6/9/2020

  Additionally, Sutro's partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration's pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1   [09-June-2020]   SOUTH SAN FRANCISCO, Calif. , June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery,

• Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

  5/21/2020

  Sutro Biopharma, Inc. announced the appointment of Craig Berman, M.D., as Vice President of Clinical Development and the promotion of Regina Cheng to Vice President of Finance and Controller.

• Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD

  5/21/2020

  Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.

• Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

  5/14/2020

  Sutro Biopharma, Inc. announced the closing of its public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which includes the exercise in full of the underwriters' option to purchase 1,650,000 shares of common stock.

• Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

  5/12/2020

  Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmu

• Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments

  5/11/2020

  STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting

• Sutro Biopharma Announces Proposed Public Offering - May 11, 2020

  5/11/2020

  Sutro Biopharma, Inc. announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock.

• Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

  4/27/2020

  Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer

• Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

  4/20/2020

  Sutro Biopharma, Inc. will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss updated dose escalation safety and efficacy data from the company's ongoing Phase I study of STRO-002 in ovarian and endometrial cancer that is being presented as a virtual poster at the AACR Virtual Annual Meeting.

• Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

  4/13/2020

  Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug conjugate (ADC) at the upcoming AACR Virtual Annual Meeting 2020.

• Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

  3/16/2020

  Sutro Biopharma today reported its financial results for the year ended December 31, 2019.